Enrollment complete in Advaxis ADXS-HPV Phase II CIN study

Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has completed enrollment of the first 40 subject cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia (CIN).

The ADXS-HPV CIN study is a randomized, single blind, placebo controlled Phase II dose-ranging study designed to assess the safety and efficacy in up to 3 different dose cohorts.

"We are pleased to complete enrollment in this cohort and take the next step towards completing the CIN study," commented Advaxis Chairman / CEO Thomas A. Moore. "The six-month follow-up evaluation for this cohort will be completed by this January. The mid-dose leg will begin recruitment immediately. Our plan is to release the low dose results in early 2012."

Source: Advaxis, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Time of starting antiretroviral therapy can influence tumor development In HIV patients